Page last updated: 2024-11-12

azd2066

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID16041426
CHEMBL ID3545164
SCHEMBL ID1848325
MeSH IDM0593468

Synonyms (20)

Synonym
mq908y1zb2 ,
934282-55-0
azd-2066
unii-mq908y1zb2
pyridine, 4-(5-((1r)-1-(5-(3-chlorophenyl)-3-isoxazolyl)ethoxy)-4-methyl-4h-1,2,4-triazol-3-yl)-
azd2066
azd 2066 [who-dd]
4-(5-{(1r)-1-[5-(3-chlorophenyl)isoxazol-3-yl]ethoxy}-4-methyl-4h-1,2,4-triazol-3-yl)pyridine
SXWHYTICXCLKDG-GFCCVEGCSA-N ,
SCHEMBL1848325
azd 2066
CHEMBL3545164
5-(3-chlorophenyl)-3-[(1r)-1-[[4-methyl-5-(4-pyridyl)-1,2,4-triazol-3-yl]oxy]ethyl]isoxazole
4-[5-[(1r)-1-[5-(3-chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4h-1,2,4-triazol-3-yl]pyridine
AKOS027470229
DB12644
HY-110255
CS-0033120
Q27284176
5-(3-chlorophenyl)-3-[(1r)-1-[(4-methyl-5-pyridin-4-yl-1,2,4-triazol-3-yl)oxy]ethyl]-1,2-oxazole

Research Excerpts

Overview

AZD2066 is a new chemical entity pharmacologically characterized as a selective, negative allosteric modulator of the metabotropic glutamate receptor subtype 5.

ExcerptReferenceRelevance
"AZD2066 is a new chemical entity pharmacologically characterized as a selective, negative allosteric modulator of the metabotropic glutamate receptor subtype 5 (mGluR5). "( A positron emission tomography study in healthy volunteers to estimate mGluR5 receptor occupancy of AZD2066 - estimating occupancy in the absence of a reference region.
Cselényi, Z; Halldin, C; Hooker, AC; Kågedal, M; Karlsson, MO; Nyberg, S; Raboisson, P; Ståhle, L; Stenkrona, P; Varnäs, K, 2013
)
2.05

Pharmacokinetics

ExcerptReferenceRelevance
" The pharmacokinetic parameters for the probe drugs and their metabolites in plasma and urinary recovery were determined."( Assessment of interaction potential of AZD2066 using in vitro metabolism tools, physiologically based pharmacokinetic modelling and in vivo cocktail data.
Andersson, A; Baranczewski, P; Nordmark, A; Ståhle, L; Wanag, E, 2014
)
0.67
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's6 (100.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 19.84

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index19.84 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (19.84)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (50.00%)5.53%
Reviews1 (16.67%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other2 (33.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]